Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

• Published in: The oncologist (Dayton, Ohio) Vol. 27; no. 10; pp. 811 - 821
• Main Authors: Wander, Seth A, O'Brien, Neil, Litchfield, Lacey M, O'Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01-10-2022
• Subjects: Academia-Pharma Intersect; Aminopyridines - pharmacology; Aminopyridines - therapeutic use; Benzimidazoles; Breast cancer; Breast Neoplasms - pathology; Care and treatment; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclins; Estrogens; Female; Health aspects; Humans; Mitogens - therapeutic use; Patient outcomes; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Tumor Suppressor Proteins; Australia; CDK4 and 6; antitumor; preclinical; breast neoplasms; abemaciclib
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyac138

Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4 and 6) are approved for the treatment of subsets of patients with hormone receptor positive (HR+) breast cancer (BC). In metastatic disease, strategies involving endocrine therapy combined with CDK4 and 6 inhibitors (CDK4 and 6i) improve clinical outcomes in HR+ BCs. CDK4 and 6i prevent retinoblastoma tumor suppressor protein phosphorylation, thereby blocking the transcription of E2F target genes, which in turn inhibits both mitogen and estrogen-mediated cell proliferation. In this review, we summarize preclinical data pertaining to the use of CDK4 and 6i in BC, with a particular focus on several of the unique chemical, pharmacologic, and mechanistic properties of abemaciclib. As research efforts elucidate the novel mechanisms underlying abemaciclib activity, potential new applications are being identified. For example, preclinical studies have demonstrated abemaciclib can exert antitumor activity against multiple tumor types and can cross the blood-brain barrier. Abemaciclib has also demonstrated distinct activity as a monotherapeutic in the treatment of BC. Accordingly, we also discuss how a greater understanding of mechanisms related to CDK4 and 6 blockade highlight abemaciclib's unique in-class properties, and could pave new avenues for enhancing its therapeutic efficacy.